Singapore HSA and research peptides — Health Products Act import and supply rules
Singapore's Health Sciences Authority (HSA) administers the Health Products Act 2007. The Health Products Act 2007 bars importing a health product without an importer's licence and supplying a health product that is not registered, except in cases prescribed by regulation; each offence carries a fine of up to S$50,000, up to 2 years' imprisonment, or both (Health Products Act 2007, ss 13 and 15). In September 2026 HSA told consumers to stop buying unapproved injectable peptides from overseas sellers and online platforms, and said "research use only" labels are used "in an attempt to circumvent regulatory controls" (HSA, 25 September 2026). This article documents that framework for Singapore researchers.
HSA is the Health Sciences Authority established under the Health Sciences Authority Act 2001, and it administers and enforces the Health Products Act 2007 (ss 2 and 6). The Act applies to the categories of health products listed in its First Schedule, and regulations made under it can prescribe "prohibited substances" that a health product may not contain (Health Products Act 2007, ss 2 and 4).
PeptideGuide could not find an HSA announcement or a Health Products Act provision that names BPC-157. HSA's published position on the wider class is its September 2026 consumer warning: unapproved injectable peptides still in clinical development, such as retatrutide and cagrilintide, are marketed online for weight loss and muscle gain; "research use only" and "not for human consumption" labels are a warning sign; and consumers should stop buying such products from unauthorised sources, including overseas sellers (HSA, 25 September 2026).
Regulation 52 of the Health Products (Therapeutic Products) Regulations 2016 lets a person import a therapeutic product for their own use, or for a member of their family, without an importer's licence. The product must not contain a psychotropic substance or more than the amounts set in the Seventh Schedule, and the quantity may not exceed 3 months' total dosage as recommended by the manufacturer, by a foreign doctor or dentist in writing, or by a qualified practitioner's prescription (regulations). HSA's guidance for travellers asks for a copy of a valid prescription or doctor's letter (HSA). PeptideGuide has not confirmed how HSA applies the exemption to products sold for research use.
PeptideGuide has no figures on how often research-peptide parcels to Singapore are intercepted. Earlier versions of this article quoted an interception rate above 50% and described customs intelligence sharing on peptide vendors, without a source; both have been removed.
Penalties under the Health Products Act: importing a health product without an importer's licence (section 13) or supplying an unregistered one (section 15) carries a fine of up to S$50,000, imprisonment of up to 2 years, or both; importing or supplying an adulterated, counterfeit or tampered-with product carries up to S$100,000, 3 years, or both (Health Products Act 2007). PeptideGuide has no data on how often individual buyers are prosecuted.
Clinical trials of therapeutic products need a Clinical Trial Authorisation (CTA) or Clinical Trial Notification (CTN) from HSA under the Health Products (Clinical Trials) Regulations, and a trial of a locally unregistered therapeutic product needs a CTA. The Clinical Trial Certificate (CTC) is the route for medicinal products under the Medicines Act (HSA, HSA).
PeptideGuide has not confirmed a lawful route for an individual in Singapore to import a peptide sold for research use, and advises Singapore residents not to order. Ask HSA before importing any unregistered product.
✓Pros
- The Act and its regulations are published in full on Singapore Statutes Online
- Regulation 52 sets out a written personal-import exemption for therapeutic products
×Cons
- Health Products Act: unlicensed import or unregistered supply carries up to S$50,000 and 2 years' imprisonment
- HSA enforces against unregistered therapeutic products with significant penalties
- PeptideGuide lists no vendor headquartered in Singapore
Is BPC-157 really banned in Singapore?
PeptideGuide could not find an HSA announcement or a Health Products Act provision that names BPC-157. The general rules apply: the Act bars importing a health product without an importer's licence and supplying an unregistered one, except in prescribed cases, and HSA warned in September 2026 that unapproved injectable peptides are sold under "research use only" labels in an attempt to circumvent regulatory controls.
What if I order BPC-157 to Singapore anyway?
If BPC-157 is treated as a health product, importing it without an importer's licence is an offence under section 13 of the Health Products Act, with a fine of up to S$50,000, up to 2 years' imprisonment, or both. PeptideGuide has no data on how often individual buyers are prosecuted.
Are other peptides treated differently?
The Health Products Act's import and supply rules do not single out any peptide, and PeptideGuide found no HSA source naming BPC-157 or another research peptide individually. HSA's September 2026 warning names retatrutide and cagrilintide as examples of unapproved injectable peptides sold online.
Can institutional researchers in Singapore work with peptides?
Clinical trials of a locally unregistered therapeutic product need a Clinical Trial Authorisation from HSA under the Health Products (Clinical Trials) Regulations (HSA). PeptideGuide has no data on which institutions use this route.
Where should Singapore-resident researchers get peptides?
PeptideGuide has not confirmed a lawful route for an individual in Singapore to import a peptide sold for research use, and advises Singapore residents not to order. Ask HSA before importing any unregistered product.
More from this region.
Other articles covering this region's vendors, regulatory framework, and research peptides.
- 2026-10-14Earlier versions said personal imports need a Health Products import permit granted only for HSA-registered products or a Therapeutic Products import licence, placed the personal-use exception in the Medicines Act and limited it to HSA-registered products, and pointed researchers to a Clinical Trials Certificate under the Health Products Regulations that A*STAR, NUS, NTU and Duke-NUS "use routinely". The personal-import exemption is regulation 52 of the Health Products (Therapeutic Products) Regulations 2016, whose text does not require registration; trials of therapeutic products need a Clinical Trial Authorisation or Notification, and the CTC is for medicinal products under the Medicines Act. Unsourced claims that Singapore Customs cooperate closely with HSA, that HSA is comparable to TGA Australia, that Singapore is the most regulatory-exposed SEA jurisdiction and that Changi is a single customs entry point were removed.
- 2026-10-14Earlier versions said HSA added BPC-157 to a "prohibited products list" in 2019 as "the only national regulator" to name it, quoted a notice for it, said the Clinical Trials Certificate pathway has excluded BPC-157 since then, said the Health Products Act's Schedule 1 lists prohibited products, and cited penalties of up to S$500,000 and 5 years. PeptideGuide could not trace any of this to HSA or the Act: the First Schedule lists the categories of health products the Act covers, and its import and unregistered-supply offences carry up to S$50,000 and 2 years (S$100,000 and 3 years for adulterated, counterfeit or tampered-with products). The ban claims and the FAQ built on them were removed and the penalties corrected.
- 2026-10-13Earlier versions said prosecution of individual buyers is rare in practice. PeptideGuide holds no data on prosecutions; the claim was removed.
- 2026-10-08Earlier versions said Singapore Customs intercepts more than 50% of research-peptide parcels "per operator-curated vendor data" and shares intelligence with HSA on known vendors. PeptideGuide holds no interception data and found no source for either claim; both were removed.